Universidad de Navarra
Organización
Ankara University
Ankara, TurquíaPublicaciones en colaboración con investigadores/as de Ankara University (47)
2024
-
Acute kidney disease beyond day 7 after major surgery: a secondary analysis of the EPIS-AKI trial
Intensive Care Medicine, Vol. 50, Núm. 2, pp. 247-257
-
Comparing thulium fiber versus high power holmium laser in bilateral same sitting retrograde intrarenal surgery for kidney stones: Results from a multicenter study
Investigative and Clinical Urology, Vol. 65, Núm. 5, pp. 451-458
-
Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.
New England Journal of Medicine, Vol. 390, Núm. 4, pp. 301-313
-
Isatuximab-pomalidomide-dexamethasone versus pomalidomide-dexamethasone in patients with relapsed and refractory multiple myeloma: final overall survival analysis
Haematologica, Vol. 109, Núm. 7, pp. 2239-2249
2023
-
Correction: “The 5th edition of The World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms” Leukemia. 2022 Jul;36(7):1720–1748 (Leukemia, (2022), 36, 7, (1720-1748), 10.1038/s41375-022-01620-2)
Leukemia
-
Improving Outcomes of Same-sitting Bilateral Flexible Ureteroscopy for Renal Stones in Real-world Practice—Lessons Learnt from Global Multicenter Experience of 1250 Patients
European Urology Open Science, Vol. 52, pp. 51-59
-
Management of multiple myeloma-related renal impairment: recommendations from the International Myeloma Working Group
The Lancet. Oncology, Vol. 24, Núm. 7, pp. e293-e311
-
Prevention and management of adverse events during treatment with bispecific antibodies and CAR T cells in multiple myeloma: a consensus report of the European Myeloma Network
The Lancet Oncology, Vol. 24, Núm. 6, pp. e255-e269
2022
-
ASTCT Clinical Practice Recommendations for Transplantation and Cellular Therapies in Multiple Myeloma
Transplantation and Cellular Therapy, Vol. 28, Núm. 6, pp. 284-293
-
Global multi-stakeholder endorsement of the MAFLD definition
The Lancet Gastroenterology and Hepatology
-
Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): follow-up analysis of a randomised, phase 3 study
The Lancet Oncology, Vol. 23, Núm. 3, pp. 416-427
-
Pomalidomide, bortezomib, and dexamethasone at first relapse in lenalidomide-pretreated myeloma: A subanalysis of OPTIMISMM by clinical characteristics
European Journal of Haematology, Vol. 108, Núm. 1, pp. 73-83
-
Prognostic Factors for Effectiveness Outcomes After Transarterial Radioembolization in Metastatic Colorectal Cancer: Results From the Multicentre Observational Study CIRT
Clinical Colorectal Cancer, Vol. 21, Núm. 4, pp. 285-296
-
The International Association for the Study of Lung Cancer Thymic Epithelial Tumor Staging Project: Unresolved Issues to be Addressed for the Next Ninth Edition of the TNM Classification of Malignant Tumors
Journal of Thoracic Oncology, Vol. 17, Núm. 6, pp. 838-851
-
Validation of the OAKS prognostic model for acute kidney injury after gastrointestinal surgery
BJS Open, Vol. 6, Núm. 1
2021
-
COVID-19 vaccination in patients with multiple myeloma: a consensus of the European Myeloma Network
The Lancet Haematology, Vol. 8, Núm. 12, pp. e934-e946
-
EPIdemiology of Surgery-Associated Acute Kidney Injury (EPIS-AKI): Study protocol for a multicentre, observational trial
BMJ Open, Vol. 11, Núm. 12
-
Efficacy and safety of oral panobinostat plus subcutaneous bortezomib and oral dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma (PANORAMA 3): an open-label, randomised, phase 2 study
The Lancet Oncology, Vol. 22, Núm. 1, pp. 142-154
-
Recommendations for vaccination in multiple myeloma: a consensus of the European Myeloma Network
Leukemia, Vol. 35, Núm. 1, pp. 31-44
-
Sin título en SCOPUS
Proceedings of the National Academy of Sciences of the United States of America, Vol. 118, Núm. 12